Biotechnology company and drug delivery platform
innovator Lexaria Bioscience
(CSE: LXX) (OTCQX: LXRP) today announced a multi-faceted expansion of
its relationship with Hill Street Beverage Company Inc. (TSX.V: BEER).
According to the update, the companies have entered into a 10-year Joint
Manufacturing Partnership (“JMP”) to produce DehydraTECH(TM) commercial
products under a new brand, which will be announced. The JMP will produce
processed THC cannabis and/or CBD hemp powder for new consumer products under
categories including, among others, tablets, capsules, or packets for sale in
Canada and for export where permitted. Similar powders as a bulk ingredient for
manufacturing processes will also be produced under the JMP for sale to other
licensed producers seeking to use Lexaria’s advanced infusion technologies to
create their own products for sale within Canada. “The new relationship between
Hill Street Beverages, One Leaf, and Lexaria Bioscience marks the beginning of
an unprecedented opportunity to deliver outstanding consumer experiences to
cannabis consumers,” Lexaria Bioscience CEO Chris Bunka said in the news
release. “We are delighted to be working with the astute branding and cannabis
expertise of the Hill Street/OneLeaf alliance team and believe that Canadian
and global cannabis consumers will benefit greatly.”
To view the full press release, visit http://ibn.fm/L0q3s
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. licenses disruptive,
patented-delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the United States and Australia for utilization of its
DehydraTECH delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates, more rapid delivery to the bloodstream, and
important taste-masking benefits for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. For more information, visit the
company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients and
other publicly traded companies on our radar. From earnings, acquisitions and
agreements to conference attendance and clinical study results, our news breaks
keep you up-to-date with the day’s top movers. MissionIR is primarily focused
on strategic communications. We have executed countless communications programs
to address the needs of companies ranging from start-ups to established
industry leaders, gaining valuable experience and the expertise necessary to
determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
